细菌溶解产物胶囊分别联合氟替美维与布地格福治疗 老年慢性阻塞性肺疾病急性加重期的疗效观察.

OBJECTIVE: To probe into the clinical efficacy of Bacterial lysate capsules respectively combined Futimeiwei and Budigefu in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in elderly patients. METHODS: A total of 100 elderly patients with AECOPD admitted to the outpatient emergency department from Oct. 2022 to May 2023 were selected to be randomly divided into Futimeiwei group and Budigefu group via random number table method, with 50 cases in each group. Both groups received regular treatment for AECOPD according to the guidelines, while taking Bacterial lysate capsules for 10 d, the Futimeiwei group was given Futimeiwei and the Budigefu group was given Budigefu, both groups continued to receive either Futimeiwei or Budigefu treatment when discharged from hospital, and the therapeutic effects were evaluated at 1 month of treatment. The evaluation indicators included blood gas analysis, lung function, inflammatory factors and adverse drug reactions. RESULTS: After treatment, the arterial partial pressure of oxygen (PaO2 ) and oxyhemoglobin saturation ( SaO2 ) of both groups were higher and the partial pressure of carbon dioxide (PaCO2 ) of both groups was lower than those before treatment, with statistically significant difference (P<0. 05); while the differences in PaO2, PaCO2 and SaO2 between two groups after treatment were not statistically significant ( P > 0. 05). After treatment, the the forced expiratory volume in 1 second ( FEV1 ), forced vital capacity ( FVC) and FEV1 / FVC of both groups were higher than those before treatment, the increasing trends of FEV1, FVC and FEV1 / FVC of Budigefu group were higher than those of Futimeiwei group, with statistically significant differences (P<0. 05). After treatment, the serum C reaction protein and interleukin 6 levels of both groups were lower than those before treatment, and those of Budigefu group was lower than the Futimeiwei group, with statistically significant differences (P<0. 05). There were no statistically significant differences in incidences of adverse drug reactions including abnormal hepatic and renal function, pneumonia, headache, rash and gastroesophageal reflux between two groups (P>0. 05). CONCLUSIONS: Bacterial lysate capsules combined with Futimeiwei and Budigefu in the treatment of AECOPD in elderly patients can effectively improve arterial [ABSTRACT FROM AUTHOR]